On November 5, 2026 Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, reported business updates and financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead," said John Leonard, M.D., Intellia President and Chief Executive Officer. "We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy. As a one-time treatment, we believe it could transform the HAE treatment paradigm while also delivering significant value to patients, physicians, payers and the overall healthcare system."

Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradykinin levels and to eliminate HAE attacks and the need for lifelong treatment.

•
In September, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of March 10, 2027. Additionally, FDA advised that it is not currently planning to hold an advisory committee to discuss the application. If approved, lonvo-z would be the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
•
Intellia significantly advanced its launch readiness in recent months, completing the deployment of its field organization and deepening its engagement with HAE treatment centers and payers in preparation for a planned commercial launch in the first quarter of 2027.

Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis

Nex-z is an in vivo CRISPR-based therapeutic candidate designed to inactivate the TTR gene in the liver, thereby preventing the production of transthyretin (TTR) protein. Nex-z offers the possibility of halting and reversing disease by driving a rapid, deep, consistent and potentially lifelong reduction in TTR protein after a one-time treatment. Intellia leads the development and commercialization of nex-z in collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron).

•
Intellia has made significant progress advancing enrollment in its MAGNITUDE Phase 3 clinical trial in ATTR amyloidosis with cardiomyopathy (ATTR-CM).
•
During the third quarter, the company completed enrollment in its MAGNITUDE-2 Phase 3 clinical trial in hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN), exceeding its targeted randomization of 60 patients.
•
During the third quarter, Intellia began providing investigators with human leukocyte antigen (HLA) genotyping results for patients enrolled or entering screening in the ongoing nex-z Phase 3 trials.

Other Recent Updates

•
In September, Intellia entered into a non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm, for up to $400 million. The transaction provides Intellia with greater financial and operational flexibility as it advances toward several key milestones, including the planned U.S. approval and commercial launch of lonvo-z in HAE.
•
In October, the company announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, she is leading the company’s translational, development, regulatory and medical affairs functions.

Upcoming Events

The company will participate in the following upcoming events:

•
November 6-9 – American Heart Association Scientific Sessions in Chicago, IL
•
November 12 – Intellia investor webcast regarding lonvo-z in HAE
•
November 12-16 – American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix, AZ

•
November 15-18 – International Symposium on Amyloidosis in Montevideo, Uruguay
•
November 17 – Jefferies London Healthcare Conference in London, England
•
December 7-9 – 23rd Global Cardiovascular Clinical Trialists Forum in Washington, D.C.

Third Quarter 2026 Financial Results

•
Cash Position: Cash, cash equivalents and marketable securities were $614.8 million as of September 30, 2026, compared to $605.1 million as of December 31, 2025. The company’s existing cash resources are expected to fund its operations at least into 2028 and well beyond lonvo-z’s anticipated U.S. approval and commercial launch in HAE in the first quarter of 2027. This guidance excludes all potential commercial revenues from lonvo-z and potential future funding from the company’s term loan facility.
•
Collaboration Revenue: Collaboration revenue was $7.2 million for the third quarter of 2026, compared to $13.8 million for the third quarter of 2025. The decrease is primarily due to a reduction in revenue from Regeneron.
•
R&D Expenses: Research and development (R&D) expenses were $83.3 million for the third quarter of 2026, compared to $94.7 million for the third quarter of 2025. The decrease was primarily driven by lower external costs related to lonvo-z, lower stock-based compensation and lower research materials and contracted services costs, partially offset by higher headcount-related expenses. Stock-based compensation expense included in R&D expenses was $7.4 million for the third quarter of 2026.
•
G&A Expenses: General and administrative (G&A) expenses were $46.1 million for the third quarter of 2026, compared to $30.5 million for the third quarter of 2025. The increase was primarily driven by consulting costs associated with the continued buildout of the company’s commercial infrastructure and higher legal, facility-related and compensation expenses. Stock-based compensation expense included in G&A expenses was $7.0 million for the third quarter of 2026.
•
Net Loss: Net loss was $127.5 million for the third quarter of 2026, compared to $101.3 million for the third quarter of 2025. Net loss for the third quarters of 2026 and 2025 included an unrealized loss of $10.4 million and an unrealized gain of $3.4 million, respectively, due to changes in the fair value of investments.

(Press release, Intellia, NOV 5, 2026, View Source [SID1234674312])

On November 5, 2026 INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, reported that it intends to offer and sell shares of its common stock in an underwritten public offering. INOVIO intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares of its common stock offered in the public offering under the same terms and conditions. All of the shares in the proposed offering will be sold by INOVIO. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies and Piper Sandler are acting as joint book-running managers for the offering.

A shelf registration statement relating to the shares of common stock offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; or Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Inovio, NOV 5, 2026, View Source [SID1234674311])

On November 5, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported its financial update for the nine months ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities," said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. "We look forward to presenting Phase 1 dose-escalation data from IPH4502, our differentiated Nectin-4 ADC, on November 18, while actively preparing for first patient dosing in the Phase 3 TELLOMAK-3 study of lacutamab in Q1 2027. We also look forward to the readout of the AstraZeneca-led PACIFIC-9 Phase 3 trial, which includes monalizumab and is now expected in the first half of 2027."

Pipeline highlights
IPH4502 (Nectin-4 exatecan ADC):
•IPH4502 is Innate Pharma’s proprietary Nectin-4-targeting ADC, combining a differentiated antibody, a proprietary stable linker and an exatecan payload, with the potential to overcome Enfortumab Vedotin (EV) resistance in urothelial carcinoma (UC) and target tumors with low or heterogeneous Nectin-4 expression beyond UC. IPH4502 is currently being evaluated in a Phase 1 trial in advanced solid tumors known to express Nectin-4 (IPH4502-101; NCT06781983).
•As announced in July 2026 (Link PR), enrollment in the Phase 1 dose-escalation of the IPH4502-101 study is complete, with 76 patients enrolled across multiple solid tumor types.
•Phase 1 dose-escalation data will be presented as a poster at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium on Molecular Targets and Cancer Therapeutics, on November 18, 2026 (Barcelona).
•Following the ENA presentation, Innate Pharma will host a hybrid event focused on IPH4502 on November 18, 2026, at 4:00 pm GMT (11:00 am ET) with in-person attendance in London at the IET London, Savoy Place and a live webcast accessible here.

Lacutamab (anti-KIR3DL2 antibody), developed in collaboration with Sobi:
•As announced on August 10, 2026 (Link PR), Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma.
•Following closing of the transaction, Innate is advancing TELLOMAK-3, the confirmatory Phase 3 study of lacutamab in Cutaneous T Cell Lymphoma (CTCL), with first patient dosing expected in Q1 2027.
•Phase 3 TELLOMAK-3 includes a confirmatory cohort in Sézary syndrome and a registrational cohort in Mycosis Fungoides.
•Innate plans an FDA filing in H2 2027 for accelerated approval in Sézary syndrome based on the existing Phase 2 TELLOMAK data once the confirmatory Phase 3 study is underway (Link PR).

Monalizumab (anti-NKG2A antibody), developed in collaboration with AstraZeneca:
•Enrollment is complete in the AstraZeneca-sponsored Phase 3 PACIFIC-9 study evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III NSCLC who have not progressed following platinum-based chemoradiation therapy.
•As announced on October 27 (Link PR), AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study.

Corporate update
•Frédéric Lombard, Chief Financial Officer, will step down from his position on December 31, 2026, to pursue new career opportunities. The Company thanks him for his contributions and dedication during his time with the Company. The Company has initiated a search of potential candidates to replace Mr. Lombard.
•As of September 30, 2026, the balance available under our April 2023 sales agreement under the At-The-Market program remains at $75 million.

Financial highlights for Q3 2026
Cash, cash equivalents and financial assets of the Company amounted to €96.8 million as of September 30, 2026, which includes the $75 million upfront payment resulting from the closing of the Sobi transaction and the aggregate gross proceeds from the €30 million private placement offering of ordinary shares that occurred in August 2026. Also as of September 30, 2026, financial liabilities amounted to €16.2 million.

Revenues for the first nine months of 2026 amounted to €3.4 million (€2.3 million for the same period in 2025). Revenue from collaboration and licensing agreements mainly results from the partial or entire recognition of the proceeds received pursuant to the co-development and license agreements with AstraZeneca and research collaboration and license agreements with Sanofi.

(Press release, Innate Pharma, NOV 5, 2026, View Source [SID1234674310])

On November 5, 2026 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, reported financial results and business highlights for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This quarter we continued to build upon our deep expertise in γδ T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform," said William Ho, CEO and co-founder of IN8bio. "It’s also exciting to see the external recognition that the unique properties of γδ T cells and their tissue-specific distribution, "may offer a unique opportunity to eliminate pathogenic cells more precisely and deeply in target organs" as stated in the Nature Reviews article. We believe this platform has the potential to enable a new class of therapeutics for autoimmune diseases and oncology, and we are excited to present our initial animal data by year-end."

Third Quarter 2026 Business Highlights

Strengthened Research and Development Leadership

•
Oxana Polyakova, Ph.D., joined IN8bio as Senior Vice President of Research & Development in September 2026, bringing 20 years of experience in γδ T cell biology, immunology, oncology, TCE and biologics development.
•
Dr. Polyakova joins IN8bio from LAVA Therapeutics, a clinical-stage immuno-oncology company developing bispecific γδ T cell engagers, where she served as Chief Scientific Officer (CSO). She previously also served as CSO at LIfT Biosciences. She was Scientific Founder and Head of Discovery at Adaptate Biotherapeutics, a γδ TCE focused spinout of GammaDelta Therapeutics, which was acquired by Takeda. At Adaptate, she designed and led its R&D strategy, established its laboratories and built its R&D team which has a program currently in the clinic. Dr. Polyakova served as the Protein and Molecular Leader at GammaDelta Therapeutics Limited that was also acquired by Takeda.
•
She will help lead R&D efforts to accelerate IN8bio’s γδ TCE pipeline toward clinical development.
Publication of INB-200 Phase 1 Data in GBM

•
In July 2026, IN8bio announced the publication of peer-reviewed clinical data from the Phase 1 trial of INB-200 (DeltEx DRI) in patients with newly diagnosed GBM in the Journal of Clinical Oncology(JCO), titled "Intracranial injection of ex vivo expanded and activated gamma-delta T cells engineered with a MGMT-expressing lentivector in patients with primary glioblastoma."
Advancing γδ T Cell Engager Platform (INB-619)

•
Continued advancing proprietary INB-600 platform of novel pan-γδ TCEs designed to selectively engage and expand γδ T cells to eliminate disease-associated target cells while potentially improving tolerability compared with conventional CD3-targeting TCEs.
•
Advancing INB-619 through preclinical studies for potential applications in oncology and autoimmune diseases.
•
INB-619 was included in a review of next-generation immune cell engagers for B cell depletion in autoimmune disease published in Nature Reviews Drug Discovery in October 2026, which noted its ability to activate and expand both tissue-resident Vδ1 and circulating Vδ2 γδ T cells in vitro.
•
Remain on track to report initial in vivo preclinical data for INB-619 by year-end 2026.
Third Quarter 2026 Financial Highlights

•
Research and Development (R&D) expenses: R&D expenses were $2.6 million for the three months ended September 30, 2026, compared with $2.1 million for the comparable prior year period. This amount includes non-cash items such as stock-based compensation (SBC) and depreciation of $0.4 million for the three months ended September 30, 2026. The increase was due primarily to preclinical costs associated with the Company’s T cell engager platform.
•
General and administrative (G&A) expenses: G&A expenses were $2.1 million for the three months ended September 30, 2026, compared with $1.9 million for the comparable prior year period. This amount includes non-cash items such as SBC and depreciation of $0.3 million for the three months ended September 30, 2026. The increase was due primarily to higher spending on professional services.

•
Net loss: The Company reported a net loss of $4.6 million, or $0.24 per basic and diluted common share, for the three months ended September 30, 2026, compared with a net loss of $3.9 million, or $0.85 per basic and diluted common share, for the comparable prior year period.
•
Cash position: As of September 30, 2026, the Company had cash of $14.0 million, compared with $10.7 million as of September 30, 2025.

(Press release, In8bio, NOV 5, 2026, View Source [SID1234674309])

On November 5, 2026 Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") reported its financial and operating results for the third quarter ended September 30, 2026, and provided an update on its recent corporate activities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels," said Dr. Helen Torley, President and Chief Executive Officer. "In and post the quarter, we have achieved multiple milestones that expand our opportunity and diversify our revenue. During the quarter, we expanded our agreements with argenx and Incyte to include additional targets to be evaluated with ENHANZE. In October, we also signed an expanded agreement with Johnson & Johnson for one additional target. Three ENHANZE programs, one each with Pfizer, Incyte and argenx advanced into Phase 1 clinical development, bringing our total products in development to twelve."

Dr. Torley continued, "In October, we also achieved an important victory in protecting our intellectual property. The Dutch specialized patent court found that Merck is infringing one of our MDASE patents and granted an injunction prohibiting the launch of Keytruda Qlex in multiple European markets. Our commitment to protecting the value of our innovations, growing royalties, continued partner expansion and growing pipeline demonstrates the power of Halozyme’s compounding platform engine and positions us to deliver durable revenue well into the next decade."

"Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026," said Darren Snellgrove, Executive Vice President and Chief Financial Officer. "We also further strengthened our financial position with the successful completion of our $1.5 billion convertible notes, which enhances our flexibility to execute our disciplined capital allocation strategy. We completed $400 million in share repurchases this year while continuing to invest in our highest-return organic opportunities and maintaining a clear path to retire our remaining 2027 and
2028 notes at maturity. With our strong cash generation, we remain focused on capital deployment to maximize long-term value creation."

Recent and Third Quarter Corporate Highlights:
•In October 2026, the Company announced the specialized Dutch patent court of the Hague found Merck Sharp & Dohme B.V. ("MSD BV"), the central European Market Authorization holder for Merck & Co., Inc., to be infringing one of Halozyme’s MDASE patents and ordered MSD BV to refrain from manufacturing, having manufactured, offering, placing on the market and using, or importing or stocking for these purposes, Keytruda Qlex in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The injunction also forbids MSD BV to facilitate infringement by its affiliates in those countries, including by allowing the use of its European Marketing Authorization. The court also rejected MSD BV’s arguments that the patent is invalid.
•During the third quarter of 2026, Halozyme repurchased approximately 0.8 million shares for $67.2 million at an average price of $79.47 per share under the May 2026 share repurchase program, resulting in $400 million of share repurchases in 2026.

Recent Partner Highlights:
•In October 2026, Takeda announced a Biologics License Application was filed with the Food and Drug Administration ("FDA") for TAK-881 for the treatment of Primary Immunodeficiency Disease.
•In October 2026, Janssen expanded its collaboration and licensing agreement with us for an additional oncology target to be developed with ENHANZE.
•In October 2026, Roche announced the FDA has approved TECENTRIQ (atezolizumab) and TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair ("dMMR") colon cancer, a type of tumour characterized by high mutation rates. This approval marks the twelfth indication for TECENTRIQ in the U.S.

Third Quarter Partner Highlights:
•In the third quarter of 2026, argenx submitted a supplemental Biologics License Application for VYVGART in ocular myasthenia gravis to the FDA.
•In September 2026, argenx expanded its collaboration and licensing agreement by nominating two additional targets which provides exclusive access to ENHANZE for a total of eight targets.
•In September 2026, Pfizer initiated a Phase 1 study to evaluate the pharmacokinetics of a single SC dose of tilrekimig with ENHANZE in healthy adults. Tilrekimig is a trispecific monoclonal antibody being developed for the treatment of atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
•In September 2026, Halozyme and Incyte expanded their collaboration to evaluate the SC formulation of axatilimab, a monoclonal antibody targeting colony-simulating factor-1 receptor, with ENHANZE. Under the terms of the new target agreement, Incyte agreed to make an upfront payment and potential future milestone payments and royalties on net sales of products developed with ENHANZE.
•In August 2026, GSK disclosed plans to initiate a Phase 1b study to evaluate the pharmacokinetics and safety of a SC belantamab formulation with ENHANZE versus IV belantamab in patients with multiple myeloma while treated with standard of care.
•The SC formulation of INCA033989, a first-in-class mutant calreticulin-targeted monoclonal antibody utilizing ENHANZE drug delivery technology is being evaluated in an ongoing Phase 1 study.

•In July 2026, Halozyme and Incyte entered into a global collaboration and license agreement to evaluate additional SC formulations of INCA033989, a first-in-class mutant calreticulin-targeted monoclonal antibody, in patients with mutant calreticulin expressing myeloproliferative neoplasms, utilizing Halozyme’s proprietary ENHANZE drug delivery technology. Under the collaboration, Incyte also has the option to nominate up to two additional targets for use with ENHANZE. Under the terms of the agreement, Incyte agreed to make an upfront payment and potential future milestone payments and royalties on net sales of products developed with ENHANZE.
•In July 2026, Janssen announced the FDA granted priority review of the supplemental Biologics License Application filing for SC amivantamab and hyaluronidase-lpuj in adults with head and neck squamous cell carcinoma.
•In the third quarter of 2026, the ongoing ARGX-119 adimanebart program was expanded to include a Phase 1 SC bioavailability study with ENHANZE.

Third Quarter 2026 Financial Highlights:
•Total revenue was $493.0 million, compared to $354.3 million in the third quarter of 2025. The 39% year-over-year increase was primarily driven by royalty revenue growth and an increase in product sales. Revenue included $341.0 million in royalties, an increase of 44% compared to $236.0 million in the third quarter of 2025, primarily driven by continued sales uptake of ENHANZE partner products that have launched since 2020, predominantly by VYVGART Hytrulo by argenx, DARZALEX SC by Janssen, and Phesgo by Roche in all geographies and contributions from other recently launched products.
•Cost of sales was $82.5 million, compared to $55.2 million in the third quarter of 2025. The increase in cost of sales was primarily due to an increase in bulk rHuPH20 sales.
•Amortization of intangibles expense was $29.5 million, compared to $17.8 million in the third quarter of 2025. The increase in amortization of intangibles expense was due to the acquisition of Elektrofi, Inc. ("Elektrofi") in November 2025.
•Research and development expense was $27.8 million, compared to $17.3 million in the third quarter of 2025. The increase was primarily due to the acquisition of Elektrofi and Surf Bio, Inc. in the fourth quarter of 2025.
•Selling, general and administrative expense was $58.2 million, compared to $46.1 million in the third quarter of 2025. The increase was primarily due to an increase in consulting and professional service fees, including litigation costs incurred in connection with a patent infringement litigation case, the acquisition of Elektrofi, and an increase in compensation expense.
•Operating income was $295.0 million, compared to $217.9 million in the third quarter of 2025.
•Net income was $247.0 million, compared to $175.2 million in the third quarter of 2025.
•EBITDA was $328.7 million, compared to $238.3 million in the third quarter of 2025. Adjusted EBITDA was $336.2 million, compared to $248.2 million in the third quarter of 2025.1
•GAAP diluted earnings per share was $2.01, compared to $1.43 in the third quarter of 2025. Non-GAAP diluted earnings per share was $2.39, compared to $1.72 in the third quarter of 2025.1
•Cash, cash equivalents, restricted cash and marketable securities were $1.08 billion on September 30, 2026, compared to $145.4 million on December 31, 2025. The increase was primarily driven by the issuance of convertible notes and cash generated from operations.

Financial Outlook for 2026
The Company is raising its 2026 financial guidance ranges, which were last updated on August 6, 2026.
For the full year 2026, the Company expects:
•Total revenue of $1.860 billion to $1.925 billion, representing growth of 33% to 38% over 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API.
•Revenue from royalties of $1.235 billion to $1.255 billion, representing growth of 42% to 45% over 2025.
•Adjusted EBITDA of $1.240 billion to $1.290 billion, representing growth of 89% to 96% over 2025, including new Hypercon and Aerocon investments of approximately $60 million.
•Non-GAAP diluted earnings per share of $8.75 to $9.05, representing growth of 111% to 118% over 2025. The Company’s earnings per share guidance includes new Hypercon and Aerocon investments of approximately $60 million and does not consider the impact of potential future share repurchases.
Table 1. 2026 Financial Guidance
Previous Guidance Range New Guidance Range
Total Revenue $1.835 to $1.910 billion $1.860 to $1.925 billion
Royalty Revenue $1.220 to $1.245 billion $1.235 to $1.255 billion
Adjusted EBITDA1
$1.225 to $1.280 billion $1.240 to $1.290 billion
Non-GAAP Diluted EPS1
$8.65 to $9.00 $8.75 to $9.05

Webcast and Conference Call
Halozyme will host its Quarterly Update Conference Call for the third quarter ended September 30, 2026 today, Thursday, November 5, 2026, at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-registration via link:View Source The call will also be webcast live through the "Investors" section of Halozyme’s corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com.

(Press release, Halozyme, NOV 5, 2026, View Source [SID1234674308])